Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.
March 25, 2014
Research has been completed on a proprietary compound called Kre-Celazine and its efficacy in treating juvenile rheumatoid/idiopathic arthritis. Jeff Golini, CEO and executive scientist at All American Pharmaceutical, developed the compound and conducted clinical research with afflicted children between the ages of seven and 16, which earned Kre-Celazine Orphan Drug Status from FDA in 2013. The research article "Kre-Celazine as a Viable Treatment for Juvenile Rheumatoid/Idiopathic Arthritis - A Pilot Study," was accepted into the Journal of Medical Food and is expected to be published later this year. Kre-Celazine is awaiting official FDA licensing for the disease indication.
Golini tentatively plans to present his arthritis research at the Federation of American Societies for Experiement biology (FASEB) during the Big Sky Montana - Nutrition Sensing and Metabolic Signaling conference later this year.
“You can expect to see more research and development coming out of All American Pharmaceutical in the coming months and years," Golini said. "Our pipeline of products is steadily increasing, as we are slowly ramping up research geared toward examining the impact of our proprietary products on various physiological conditions."
You May Also Like
Five tips for creating an irresistible snack bar – articleMar 1, 2024
SupplySide Education Series: Microbiome: Beyond probiotics – webinarMar 21, 2024
A self-regulated supplement industry is the path to responsible innovationFeb 29, 2024
Pomegranate seed oil preserves memory in studyFeb 28, 2024